Polypharmacy is associated with frailty in Japanese community-dwelling older adults

被引:23
作者
Yuki, Atsumu [1 ]
Otsuka, Rei [2 ]
Tange, Chikako [2 ]
Nishita, Yukiko [2 ]
Tomida, Makiko [2 ]
Ando, Fujiko [3 ]
Shimokata, Hiroshi [4 ]
机构
[1] Kochi Univ, Fac Educ, 2-5-1 Akebono, Kochi, Kochi 7808520, Japan
[2] Natl Ctr Geriatr & Gerontol, Sect NILS LSA, Morioka, Iwate, Japan
[3] Aichi Shukutoku Univ, Fac Hlth & Med Sci, Nagakute, Aichi, Japan
[4] Nagoya Univ Arts & Sci, Grad Sch Nutr Sci, Nisshin, Japan
关键词
community-dwelling; logistic regression; medications; National Institute for Longevity Sciences-Longitudinal Study of Aging; randomly chosen; CLINICAL-PRACTICE; RISK; GUIDELINES; OUTCOMES; PEOPLE; COHORT;
D O I
10.1111/ggi.13507
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
AimThe association between polypharmacy and the development of frailty is unknown. The present study assessed the longitudinal relationship between polypharmacy and frailty risk in Japanese community-dwelling older adults. MethodsParticipants included 299 non-frail older Japanese adults aged 65-81years who participated in both baseline and follow-up examinations of a longitudinal study of aging (mean duration 6.2years). At baseline examination, all prescribed and non-prescribed medications used during the previous 2weeks were confirmed and coded by physicians. Frailty was diagnosed according to frailty criteria, and included shrinking, exhaustion, low activity, low grip strength and low gait speed. The relationship between frailty and the number of medications was assessed using multiple logistic regression analysis. The logistic regression model was used to control for potential confounders, including age at baseline, sex, body fat, total physical activity, education, employment, current smoking and number of comorbidities. ResultsThe percentage of participants who developed frailty during follow up was 5.1% in those taking five or fewer medications, and 22.5% in those taking six or more medications. The fully adjusted odds ratio for frailty among participants taking six or more medications was 5.55 (95% confidence interval 2.17-14.22). ConclusionsPolypharmacy appears to be a significant risk factor for the development of frailty in older Japanese adults. Geriatr Gerontol Int 2018; 18: 1497-1500.
引用
收藏
页码:1497 / 1500
页数:4
相关论文
共 20 条
[1]  
Arai H, 2014, STATEMENT OF FRAILTY
[2]  
Cabinet Office G of J, 2017, ANN REP AG SOC 2017
[3]   The Asia-Pacific Clinical Practice Guidelines for the Management of Frailty [J].
Dent, Elsa ;
Lien, Christopher ;
Lim, Wee Shiong ;
Wong, Wei Chin ;
Wong, Chek Hooi ;
Ng, Tze Pin ;
Woo, Jean ;
Dong, Birong ;
de la Vega, Shelley ;
Poi, Philip Jun Hua ;
Kamaruzzaman, Shahrul Bahyah Binti ;
Won, Chang ;
Chen, Liang-Kung ;
Rockwood, Kenneth ;
Arai, Hidenori ;
Rodriguez-Manas, Leocadio ;
Cao, Li ;
Cesari, Matteo ;
Chan, Piu ;
Leung, Edward ;
Landi, Francesco ;
Fried, Linda P. ;
Morley, John E. ;
Vellas, Bruno ;
Flicker, Leon .
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2017, 18 (07) :564-575
[4]   Frailty in older adults: Evidence for a phenotype [J].
Fried, LP ;
Tangen, CM ;
Walston, J ;
Newman, AB ;
Hirsch, C ;
Gottdiener, J ;
Seeman, T ;
Tracy, R ;
Kop, WJ ;
Burke, G ;
McBurnie, MA .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2001, 56 (03) :M146-M156
[5]   Health Outcomes Associated with Polypharmacy in Community-Dwelling Older Adults: A Systematic Review [J].
Fried, Terri R. ;
O'Leary, John ;
Towle, Virginia ;
Goldstein, Mary K. ;
Trentalange, Mark ;
Martin, Deanna K. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2014, 62 (12) :2261-2272
[6]   Pharmacogenetics, drug-metabolizing enzymes, and clinical practice [J].
Gardiner, Sharon J. ;
Begg, Evan J. .
PHARMACOLOGICAL REVIEWS, 2006, 58 (03) :521-590
[7]   Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes [J].
Gnjidic, Danijela ;
Hilmer, Sarah N. ;
Blyth, Fiona M. ;
Naganathan, Vasi ;
Waite, Louise ;
Seibel, Markus J. ;
McLachlan, Andrew J. ;
Cumming, Robert G. ;
Handelsman, David J. ;
Le Couteur, David G. .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2012, 65 (09) :989-995
[8]   Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations [J].
Inoue, K ;
Yamazaki, H ;
Imiya, K ;
Akasaka, S ;
Guengerich, FP ;
Shimada, T .
PHARMACOGENETICS, 1997, 7 (02) :103-113
[9]   Clinical consequences of cytochrome P4502C9 polymorphisms [J].
Kirchheiner, J ;
Brockmöller, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (01) :1-16
[10]   Polypharmacy as a Risk Factor for Clinically Relevant Sarcopenia: Results From the Berlin Aging Study II [J].
Koenig, Maximilian ;
Spira, Dominik ;
Demuth, Ilja ;
Steinhagen-Thiessen, Elisabeth ;
Norman, Kristina .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2018, 73 (01) :117-122